Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Operating Leases (2017 - 2025)

AC Immune has reported Operating Leases over the past 8 years, most recently at $4.6 million for Q4 2025.

  • Quarterly Operating Leases fell 8.13% to $4.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.6 million through Dec 2025, down 8.13% year-over-year, with the annual reading at $4.6 million for FY2025, 8.13% down from the prior year.
  • Operating Leases was $4.6 million for Q4 2025 at AC Immune, up from $4.5 million in the prior quarter.
  • Over five years, Operating Leases peaked at $3.2 billion in Q4 2023 and troughed at $2.0 million in Q3 2022.
  • The 5-year median for Operating Leases is $3.8 million (2024), against an average of $607.9 million.
  • Year-over-year, Operating Leases skyrocketed 140132.61% in 2021 and then tumbled 99.91% in 2022.
  • A 5-year view of Operating Leases shows it stood at $2.5 billion in 2021, then plummeted by 99.91% to $2.3 million in 2022, then surged by 136079.34% to $3.2 billion in 2023, then tumbled by 99.84% to $5.0 million in 2024, then dropped by 8.13% to $4.6 million in 2025.
  • Per Business Quant, the three most recent readings for ACIU's Operating Leases are $4.6 million (Q4 2025), $4.5 million (Q3 2025), and $4.7 million (Q2 2025).